What does QureBio do?
PhnyX Lab leverages generative AI to streamline operations in the life science sector through its product Cheiron, which assists companies in tasks such as research paper and clinical trial searches.
How much did they raise?
The company closed a $4M seed round via a SAFE, with the round led by SK Networks and participation from notable angel investors including Aidan Gomez and Illia Polosukhin, key figures in the development of modern generative AI.
What are their plans for the money?
With the funding, PhnyX Lab plans to expand its product suite, including advancing Cheiron Write, which aims to automate medical writing and drastically reduce documentation time from months to weeks or even hours.
What have they achieved so far?
Since its launch in December 2024, Cheiron has gained traction with over 60 companies, including all of Korea's top 10 pharmaceutical firms by revenue, and the company has already secured strategic partnerships with SK Biopharmaceuticals and Samil Pharmaceutical.
